23:21 , Mar 27, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer; lymphoma; solid tumors Cell culture and mouse studies suggest inhibiting RALBP1 could help treat cancer. In cell lines of human renal cell carcinoma (RCC), pancreatic cancer, non-small cell lung cancer (NSCLC) and three...
08:00 , Feb 5, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Programmed cell death 1 (PD-1; PDCD1; CD279); asparagine-linked glycosylation 8 (ALG8); laminin α subunit 4 (LAMA4); ADP-dependent glucokinase (AD

Cancer INDICATION: Cancer Two studies in mice suggest tumor vaccines based on tumor-specific mutant antigens could help improve the efficacy of therapies targeting PD-1 and other checkpoint inhibitors. In a mouse model of anti-PD1-treated sarcoma,...
08:00 , Jan 29, 2015 |  BC Innovations  |  Targets & Mechanisms

Personalized tumor vaccines

Although the jury is in on the role of PD-1 inhibitors in enabling T cell activation in cancer, it is still unclear which tumor epitopes are targeted by the T cells or whether those epitopes...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Company News

Merganser Biotech, Terapio, National Institutes of Health, University of North Carolina hematology, neurology, other news

NIH selected three preclinical projects to receive no-cost access to NIH development contractor resources under its Bridging Interventional Development Gaps (BrIDGs) program. The program aims to help projects from academic institutions, not-for-profits and Small Business...